Use of a Mouse Model of Pancreatic Neuroendocrine Tumors to Find Pericyte Biomarkers of Resistance to Anti-angiogenic Therapy

Hormone and Metabolic Research

Volumn 43, Issue 12, 2011, Pages 884-889

  Franco, M ^a   Paez Ribes M ^b   Cortez, E ^a   Casanovas, O ^b   Pietras, K ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

angiogenesis; mouse models of cancer; targeted therapy; therapeutic resistance

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY DC101; TUMOR MARKER; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ARTICLE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PANCREAS ISLET CELL TUMOR; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; TREATMENT RESPONSE; ANIMAL CELL; CANCER RESISTANCE; CONTROLLED STUDY; DISEASE MARKER; LONG TERM CARE; NEUROENDOCRINE TUMOR; PANCREAS; PANCREAS CANCER; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR;

EID: 82155191786     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1284381     Document Type: Article

References (29)

1. Fazio N., Cinieri S., Lorizzo K., Squadroni M., Orlando L., Spada F., Maiello E., Bodei L., Paganelli G., Delle Fave G., de Braud F. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer Treat Rev: 2010; 36 03 S87 S94
2. Kerbel R. S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther: 2003; 2 S134 S139
3. de Jonge M. J., Verweij J. Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all? Eur J Cancer: 2006; 42 1351 1356
4. Karapetis C. S., Khambata-Ford S., Jonker D. J., O'Callaghan C. J., Tu D., Tebbutt N. C., Simes R. J., Chalchal H., Shapiro J. D., Robitaille S., Price T. J., Shepherd L., Au H. J., Langer C., Moore M. J., Zalcberg J. R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med: 2008; 359 1757 1765
5. Kerbel R. S. Tumor angiogenesis. N Engl J Med: 2008; 358 2039 2049
6. Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation. Cell: 2011; 144 646 674
7. Bergers G., Javaherian K., Lo K. M., Folkman J., Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science: 1999; 284 808 812
8. Roberts W. G., Whalen P. M., Soderstrom E., Moraski G., Lyssikatos J. P., Wang H. F., Cooper B., Baker D. A., Savage D., Dalvie D., Atherton J. A., Ralston S., Szewc R., Kath J. C., Lin J., Soderstrom C., Tkalcevic G., Cohen B. D., Pollack V., Barth W., Hungerford W., Ung E. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res: 2005; 65 957 966
9. Noguera-Troise I., Daly C., Papadopoulos N. J., Coetzee S., Boland P., Gale N. W., Lin H. C., Yancopoulos G. D., Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature: 2006; 444 1032 1037
10. Cunha S. I., Pardali E., Thorikay M., Anderberg C., Hawinkels L., Goumans M. J., Seehra J., Heldin C. H., Ten Dijke P., Pietras K. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med: 2010; 207 85 100
11. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature: 1985; 315 115 122
12. Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose chemo-switch regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol: 2005; 23 939 952
13. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell: 2009; 15 220 231
14. Raymond E., Dahan L., Raoul J. L., Bang Y. J., Borbath I., Lombard-Bohas C., Valle J., Metrakos P., Smith D., Vinik A., Chen J. S., Horsch D., Hammel P., Wiedenmann B., Van Cutsem E., Patyna S., Lu D. R., Blanckmeister C., Chao R., Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med: 2011; 364 501 513
15. Gaengel K., Genove G., Armulik A., Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol: 2009; 29 630 638
16. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R. K., McDonald D. M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol: 2002; 160 985 1000
17. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest: 2003; 111 1287 1295
18. Erber R., Thurnher A., Katsen A. D., Groth G., Kerger H., Hammes H. P., Menger M. D., Ullrich A., Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J: 2004; 18 338 340
19. Lu C., Thaker P. H., Lin Y. G., Spannuth W., Landen C. N., Merritt W. M., Jennings N. B., Langley R. R., Gershenson D. M., Yancopoulos G. D., Ellis L. M., Jaffe R. B., Coleman R. L., Sood A. K. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol: 2008; 198 477 e471 e479 discussion 477 e479-e410
20. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res: 2010; 316 1324 1331
21. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer: 2008; 8 592 603
22. Casanovas O., Hicklin D. J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell: 2005; 8 299 309
23. Song S., Ewald A. J., Stallcup W., Werb Z., Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol: 2005; 7 870 879
24. Trotter J., Karram K., Nishiyama A. NG2 cells: Properties, progeny and origin. Brain Res Rev: 2010; 63 72 82
25. Sugimoto H., Mundel T. M., Kieran M. W., Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther: 2006; 5 1640 1646
26. Sennino B., Falcon B. L., McCauley D., Le T., McCauley T., Kurz J. C., Haskell A., Epstein D. M., McDonald D. M. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res: 2007; 67 7358 7367
27. Helfrich I., Scheffrahn I., Bartling S., Weis J., von Felbert V., Middleton M., Kato M., Ergun S., Schadendorf D. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med: 2010; 207 491 503
28. Hasumi Y., Klosowska-Wardega A., Furuhashi M., Ostman A., Heldin C. H., Hellberg C. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer: 2007; 121 2606 2614
29. Jann H., Wertenbruch T., Pape U., Ozcelik C., Denecke T., Mehl S., Wiedenmann B., Pavel M. A matter of the heart: myocardial metastases in neuroendocrine tumors. Horm Metab Res: 2010; 42 967 976